Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background.

Yu J, Marsh S, Hu J, Feng W, Wu C.

Gastroenterol Res Pract. 2016;2016:2862173. doi: 10.1155/2016/2862173. Epub 2016 May 9. Review.

2.

Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome.

Wainwright P, Byrne CD.

Int J Mol Sci. 2016 Mar 11;17(3). pii: E367. doi: 10.3390/ijms17030367. Review.

3.

Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia.

Hu M, Yang YL, Ng CF, Lee CP, Lee VW, Hanada H, Masuda D, Yamashita S, Tomlinson B.

Medicine (Baltimore). 2015 May;94(20):e881. doi: 10.1097/MD.0000000000000881.

4.

The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes.

Perry RJ, Samuel VT, Petersen KF, Shulman GI.

Nature. 2014 Jun 5;510(7503):84-91. doi: 10.1038/nature13478. Review.

5.

Role of mitochondria in nonalcoholic fatty liver disease.

Nassir F, Ibdah JA.

Int J Mol Sci. 2014 May 15;15(5):8713-42. doi: 10.3390/ijms15058713. Review.

6.

Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH).

Takaki A, Kawai D, Yamamoto K.

Int J Mol Sci. 2014 Apr 29;15(5):7352-79. doi: 10.3390/ijms15057352. Review.

7.

Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH).

Takaki A, Kawai D, Yamamoto K.

Int J Mol Sci. 2013 Oct 15;14(10):20704-28. doi: 10.3390/ijms141020704. Review.

8.

Balancing the fat: lipid droplets and human disease.

Krahmer N, Farese RV Jr, Walther TC.

EMBO Mol Med. 2013 Jul;5(7):905-15. doi: 10.1002/emmm.201100671. Epub 2013 Jun 6. Review.

9.

Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease.

Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A.

Nutrients. 2013 May 10;5(5):1544-60. doi: 10.3390/nu5051544. Review.

10.

Increased expression of enzymes of triglyceride synthesis is essential for the development of hepatic steatosis.

Jin J, Iakova P, Breaux M, Sullivan E, Jawanmardi N, Chen D, Jiang Y, Medrano EM, Timchenko NA.

Cell Rep. 2013 Mar 28;3(3):831-43. doi: 10.1016/j.celrep.2013.02.009. Epub 2013 Mar 14.

11.

Liver and diabetes. A vicious circle.

Loria P, Lonardo A, Anania F.

Hepatol Res. 2013 Jan;43(1):51-64. doi: 10.1111/j.1872-034X.2012.01031.x.

12.

Dissociating fatty liver and diabetes.

Sun Z, Lazar MA.

Trends Endocrinol Metab. 2013 Jan;24(1):4-12. doi: 10.1016/j.tem.2012.09.005. Epub 2012 Oct 5. Review.

13.

Lactase persistence and lipid pathway selection in the Maasai.

Wagh K, Bhatia A, Alexe G, Reddy A, Ravikumar V, Seiler M, Boemo M, Yao M, Cronk L, Naqvi A, Ganesan S, Levine AJ, Bhanot G.

PLoS One. 2012;7(9):e44751. doi: 10.1371/journal.pone.0044751. Epub 2012 Sep 28.

14.

Hepatic ATGL knockdown uncouples glucose intolerance from liver TAG accumulation.

Ong KT, Mashek MT, Bu SY, Mashek DG.

FASEB J. 2013 Jan;27(1):313-21. doi: 10.1096/fj.12-213454. Epub 2012 Sep 19.

15.

Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients.

Hu M, Chu WC, Yamashita S, Yeung DK, Shi L, Wang D, Masuda D, Yang Y, Tomlinson B.

J Lipid Res. 2012 Apr;53(4):802-9. doi: 10.1194/jlr.P023614. Epub 2012 Feb 7.

16.

The metabolically benign and malignant fatty liver.

Stefan N, Häring HU.

Diabetes. 2011 Aug;60(8):2011-7. doi: 10.2337/db11-0231. No abstract available.

17.

Mammalian triacylglycerol metabolism: synthesis, lipolysis, and signaling.

Coleman RA, Mashek DG.

Chem Rev. 2011 Oct 12;111(10):6359-86. doi: 10.1021/cr100404w. Epub 2011 Jun 1. Review. No abstract available.

18.

Genetic determinants of hepatic steatosis in man.

Hooper AJ, Adams LA, Burnett JR.

J Lipid Res. 2011 Apr;52(4):593-617. doi: 10.1194/jlr.R008896. Epub 2011 Jan 18. Review.

19.

Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease.

Hotta K, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, Chayama K, Nakajima A, Nakao K, Sekine A.

BMC Med Genet. 2010 Dec 22;11:172. doi: 10.1186/1471-2350-11-172.

20.

Liver fat content determined by magnetic resonance imaging and spectroscopy.

Springer F, Machann J, Claussen CD, Schick F, Schwenzer NF.

World J Gastroenterol. 2010 Apr 7;16(13):1560-6. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk